The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: September 2010

More OETF Investments Announced, Including NeurAxon

The Ontario Emerging Technologies Fund got off to a bit of a slow start on the life sciences front, but last month it added Lumira and CTI Life Sciences as qualified investors. Now, CTI has taken advantage of that status with OETF participating in a $14 million round of convertible debentures issued by NeurAxon, along [...]

Biotech Trends Update — IP Constituencies: Endo’s Qualitest Purchase Shows Full Integration of Innovator and Generic Strategies

Endo Pharmaceuticals (NASDAQ: ENDP) announced yesterday morning that it will spend $1.2 billion to buy U.S. generics company Qualitest Pharmaceuticals. Endo also has an active pipeline of “innovative” products in development, emphasizing the industry trend we’ve been following of a narrowing distinction between innovator and generics companies. Endo began its modern existence after being spun [...]

Monday Biotech Deal Review: September 27, 2010

Welcome to your Monday Biotech Deal Review. I am very excited to be writing for The Cross-Border Biotech Blog after working with Jeremy behind the scenes over the past three years. [ed. welcome (back) aboard!] It was a busy week for Canadian biotech companies, so let’s get started.

This Week in the Twitterverse

Lots of great weekend reading from our Twitter stream on @crossborderbio, including a plane that flies like a bird, a $450 million licensing deal and links to several worthwhile upcoming events:

Cross-Border Biotech Blog News: Favourite Features Returning With New Authors

I’m excited to announce that the Monday Biotech Deal Review and the Friday Science Review will be back next week to restart your regular dosing of Canada’s Biotech inventions and transactions. The Monday Deal Review will be authored by Jacob Cawker, who has worked with me on the blog in various capacities over the past three years. [...]

Why Technology Transfer Offices Should Focus on Sponsored Research and Ignore Royalties: In Praise of UNC’s “Express License”

A story by Xconomy’s Sylvia Pagán Westphal yesterday highlights a new approach to technology transfer licensing being taken by UNC Chapel Hill’s Office of Technology Development: The Carolina Express License. At first glance, the agreement looks, as Westphal puts it, “not very sweet for the university.” UNC takes 0.75% of any exit transaction, but no equity, no milestones [...]

Biotech Trends Update — Biosimilars: FDA Meeting in November to Discuss BCPI Act Implementation

Adam Feuerstein at TheStreet.com reported this morning on a draft FDA notice for a planned November meeting on implementation of the Biologics Price Competition and Innovation Act, which was passed as part of the healthcare reform legislation. The BPCI Act (42 U.S.C. 262(k)(8)) provides for the FDA to author guidance “with respect to the licensure [...]

Flow-Through Shares for Biotech: Welcome to National Biotechnology Week in Canada

Tomorrow is the first day of National Biotechnology Week in Canada. The imagenation.ca website has lots of info, and you can follow @BIOTECanadaNBW on Twitter. One of this year’s big policy initiatives is a push to expand Canada’s Flow-Through Shares program from mining and wind power to include biotech and other cleantech companies. I gave [...]

Agricultural Biotechnology International Conference (ABIC) In Saskatoon This Week Highlights Canada’s Strength in Ag-Biotech

The ABIC conference in Saskatoon this week is highlighting Canada’s strength in the field (har). Canada has world-class resources to compete: plenty of arable and marginal land, and bushels (sorry) of know-how and innovation. Two Canadian announcements of note at the conference: Saskatchewan’s Premier, Brad Wall, announced $5 million over 4 years for ag-bio projects. The [...]

Follow

Get every new post delivered to your Inbox.

Join 76 other followers